Novartis Hellas SACI

Member: Gold
Since: 01.03.2016

12th km National Road Athens-Lamia, Metamorfosi, 144 51 Athens, Greece

RSS

Novartis: Susanne Kohout - Our mission is to help people live longer and better

05.05.2021 Share

She took over as head of Novartis Hellas in 2017, in a period of intense challenges for our country and her company. With clear positions on everything, the German-born President and CEO of the powerful pharmaceutical company favours innovative partnerships for the creation of a sustainable future and equal opportunities regardless of gender, and points out that inclusive societies must be the focus now and after the end of the health crisis caused by the pandemic.

With a degree in business administration from the University of Cologne, Susanne Kohout, a Novartis executive since 1996, is the woman who led the process of the merger of Ciba and Sandoz Self-Medication with Novartis’ Consumer Health arm. Since then, she has held several positions of responsibility in the leading pharmaceutical firm. She refers proudly to the achievements of the company that she represents and its strong position in the global market, and in the conversation that follows she explains the need for all stakeholders – organizations, companies, governments and societies – to redefine their approach to healthcare.

Mrs Kohout, one year into the pandemic, what is the one thing that concerns you the most?

The whole world was taken by storm from the pandemic and -apart from the human toll- one of the side effects observed is people neglecting other serious health conditions. Experience from the first lockdown showed significant delays in the treatment of chronic illnesses. Surgeries were postponed, patients were afraid to visit their doctors, and this could have social and economic repercussions. Prevention, early diagnosis, and proper treatment of all other illnesses should continue to be our priority. In order to avoid a major public health crisis in the coming years, a broader approach to the situation is needed, as the COVID-19 pandemic is only one of the many crises we are facing. We aren’t merely facing a once-in-a-century pandemic. We’re facing a syndemic: the confluence of several epidemics. To address these unmet needs and meet the syndemic head on, we need to reimagine our approach to health care.

What are your top priorities and your greatest challenge, as Country President and Managing Director of Novartis Hellas?

The impact of the global COVID-19 pandemic has demonstrated that fulfilling our mission as Novartis, to help people live longer and better lives, is more necessary and relevant than ever. Looking towards the future, we realize more and more clearly that each of our contributions is part of a broader movement of solidarity and cooperation, since the new challenges faced by humanity, countries and health systems are far too big and complex to be solved by individual groups, organizations or governments. Working together is essential to create a sustainable future and Novartis is here to provide solutions in this direction. Furthermore, our people are our most valuable resource. We want everyone to feel able to be their best selves at work and at home, and we are committed to supporting and enabling them to be inspired, curious and unbossed. The global pandemic has accelerated our organizational need to explore new working and training models. We focused on the protection of our employees’ health, the safety of healthcare professionals and the seamless delivery of our treatments to Greek patients. To further support the development our people, we provide access to top training providers, but we also expanded the free access to Coursera and Khan Academy digital education platforms to our employees’ families.

How do you evaluate the handling of the pandemic in Greece, compared to other European countries?

When facing an unprecedented crisis, such as the one we continue to face today, we are on a constant journey of experimenting & learning, therefore a masterplan is never enough. It is certain that many decisions are going to be questioned, or possibly, wrong, others are going to be valid or fruitful and set a foundation for corrective action. The Covid-19 pandemic has demonstrated that health is the crucial factor for the happiness and prosperity of our societies. In an undisputable manner, it revealed the many interdependencies among society, health, economy, business, politics, and science. It made evident that the health challenges we are facing today are far too big and complex to solve by individual groups, organizations, or governments, and cooperation is key. I recently had my vaccination in Athens and I was really impressed by the operational excellence of the Greek state in this matter.

You have been serving Novartis in key positions since 1996. During these years, the company discovered and placed on the market medicines and therapies that changed the course of many serious diseases. When did you feel that the company literally “made history”?

On March 7, 1996, the Swiss pharmaceutical companies Ciba-Geigy and Sandoz announced what was at the time the biggest merger in the history of the industry. Novartis was born with the vision of accelerating innovation and asserting an even stronger position on the global markets. Together with our predecessor companies, the collective heritage roots back more than 250 years, with a rich history of developing innovative products. Over the past 25 years, Novartis has achieved medical breakthroughs in blood cancer care, heart disease, multiple sclerosis and the fight against inflammatory conditions with therapies that are changing the course of medical history as they are seriously benefiting the lives of thousands of patients all over the world. Looking at the next 25 years and beyond, Novartis will continue reimagining medicine to improve and extend people’s lives. Cell and gene therapies that only need to be administered once for patients with serious, rare and life-threatening diseases are creating a new turning point in medicine and how we treat diseases. The development of cell and gene therapies has been pivotal for innovation in the field and presents the opportunity to reexamine how our healthcare system manages diagnosis, treatment, care and associated costs for patients.

You live in Greece since 2017, when you took over the position of Country President & Managing Director of Novartis Hellas. What are the things that have been intriguing and difficult for you during these three years in our country?

I joined the company at a challenging time, both locally & globally. As a person, I always choose to see challenges as opportunities for learning and further growth. Since then, we remain committed to the Greek market and we are on a journey to supply patients with life-saving therapies twice as fast, provide innovative solutions for our customers and the Healthcare system. I am confident and proud that our efforts are being recognized; the 2020 Fortune Greece Most Admired Companies award as No1 Pharma company in the country reflects just that.

Trust and reliability are at the top of society’s concerns when choosing products and services, especially when these are related to health. What makes a pharmaceutical company credible and how is trust built in times of uncertainty and financial crisis?

A big part of gaining this trust is being transparent. For many years, transparent reporting has been a central part of our commitment, as we publish locally an annual ‘Novartis in Society’ ESG (Environmental, Social & Governance) report. Most recently, we have published the results of our Corporate Responsibility Report for 2018-2019, fully in line with the principles of the Global Compact and the Goals for Sustainable Development of the UN. More specifically, Novartis Hellas returned 53% of its revenues to the Greek society and economy in 2018-2019, through investments in R&D, social programs and our supply chain. We have a strong footprint in the access to medicines, providing 54 of our treatments to 1.7 million patients, and conducting more than 70 clinical trials to approximately 2500 patients with a zero cost for the Greek healthcare system.

Can uninsured patients or patients without financial capacity have access to your medicines and innovative therapies?

Improving access to medicines remains one of the greatest healthcare needs worldwide. According to the World Health Organization (WHO), one-quarter of the world’s population – 2 billion people – have no access to basic medicines. Roughly, 1 billion people faced catastrophic payments for healthcare in 2020, driven in large part by out-of-pocket spending on medicines.

Collectively, the global health community has a responsibility to help ensure that no one is left behind and that anyone who requires treatment receives it. We established the Novartis access principles in 2017 to systematically integrate access strategies into how we research, develop and deliver our new medicines globally. This is a key measure of success for our leaders and associates. Our emerging markets center of excellence in our Pharmaceuticals business unit supports the implementation of the principles by ingraining access into all new launches in LMICs. Strategies can include establishing innovative pricing and access models, driving early launches in these countries, and supporting approaches to strengthen healthcare systems. In Greece, pharmaceutical care of uninsured citizens is covered by the state. We fully support the leverage of appropriate funding by using social welfare accounts as it has been fulfilled in the recent past.

Novartis is ranked amongst the companies most heavily investing in R&D globally and this has been your strategic priority. How many years can research for a product last and in what aspects is the contribution of new technologies most critical?

It can take years to produce breakthrough medicines. However, new technologies can help us speed up the process. Researchers are still uncovering the many ways the various techniques can be used to enhance and speed up drug discovery. The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients. Research teams are actively pursuing disruptive technology, scouring academic labs for new inventions and launching collaborations to push the development of equipment in a direction that will benefit scientists working in drug discovery.

For example, Novartis has an extensive experience & pipeline in neurodegenerative diseases. A great example of collaboration with academia is EuroNeurotrophin, which is a European training network for the development of neurotrophin small molecule mimetics as candidate therapeutic agents for neurodegeneration and neuroinflammation. Novartis Hellas came into agreement with the Consortium and the Marie-Curie European Training Network EuroNeurotrophin, funded by the Horizon 2020, becoming a Board Member of this innovative project. EuroNeurotrophin will enable the non-academic partners to increase their innovation capacity by (a) having access to the generated new knowledge and relevant technologies (b) giving them a “pre-emption” right to patent specific findings and (c) recruit strong post graduates or post docs (early stage researchers) into the business acting as a long term ‘feeder’ programme for junior medical roles.

Novartis Hellas SACI

Novartis: Susanne Kohout - Our mission is to help people live longer and better

Photos

CORPORATE

NGO

SOCIETY